DE69429927D1 - Fettsäure-abgabesystem - Google Patents

Fettsäure-abgabesystem

Info

Publication number
DE69429927D1
DE69429927D1 DE69429927T DE69429927T DE69429927D1 DE 69429927 D1 DE69429927 D1 DE 69429927D1 DE 69429927 T DE69429927 T DE 69429927T DE 69429927 T DE69429927 T DE 69429927T DE 69429927 D1 DE69429927 D1 DE 69429927D1
Authority
DE
Germany
Prior art keywords
fatty acid
supply system
acid supply
fatty
supply
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69429927T
Other languages
English (en)
Other versions
DE69429927T2 (de
Inventor
Geoffrey Anisson
David Topping
Richard Illman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commonwealth Scientific and Industrial Research Organization CSIRO
Original Assignee
Commonwealth Scientific and Industrial Research Organization CSIRO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commonwealth Scientific and Industrial Research Organization CSIRO filed Critical Commonwealth Scientific and Industrial Research Organization CSIRO
Application granted granted Critical
Publication of DE69429927D1 publication Critical patent/DE69429927D1/de
Publication of DE69429927T2 publication Critical patent/DE69429927T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A21BAKING; EDIBLE DOUGHS
    • A21DTREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
    • A21D2/00Treatment of flour or dough by adding materials thereto before or during baking
    • A21D2/08Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
    • A21D2/14Organic oxygen compounds
    • A21D2/16Fatty acid esters
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12Fatty acids or derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
DE69429927T 1993-11-17 1994-11-17 Fettsäure-abgabesystem Expired - Lifetime DE69429927T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPM245493 1993-11-17
PCT/AU1994/000713 WO1995013801A1 (en) 1993-11-17 1994-11-17 Fatty acid delivery system

Publications (2)

Publication Number Publication Date
DE69429927D1 true DE69429927D1 (de) 2002-03-28
DE69429927T2 DE69429927T2 (de) 2002-11-07

Family

ID=3777356

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69429927T Expired - Lifetime DE69429927T2 (de) 1993-11-17 1994-11-17 Fettsäure-abgabesystem

Country Status (6)

Country Link
US (1) US5840860A (de)
EP (1) EP0730447B1 (de)
JP (1) JP4071823B2 (de)
CA (1) CA2176719C (de)
DE (1) DE69429927T2 (de)
WO (1) WO1995013801A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO763197A0 (en) * 1997-06-30 1997-07-24 Sigma Pharmaceuticals Pty Ltd Health supplement
CA2317744A1 (en) * 1998-01-23 1999-07-29 Smithkline Beecham Corporation Cellulose derivatives and colorectal cancer risk reduction
AU773195B2 (en) * 1999-07-01 2004-05-20 Commonwealth Scientific And Industrial Research Organisation Nasogastric enteral formulations
AUPQ132599A0 (en) * 1999-07-01 1999-07-22 Commonwealth Scientific And Industrial Research Organisation Nasogastric enteral formulations
AUPQ851000A0 (en) * 2000-06-30 2000-07-27 Commonwealth Scientific And Industrial Research Organisation Rapid fatty acid delivery
US6866862B2 (en) * 2001-10-05 2005-03-15 Rubicon Scientific Animal feeds including heartworm-prevention drugs
US6716448B2 (en) 2001-10-05 2004-04-06 Rubicon Scientific Llc Domesticated household pet food including maintenance amounts of ivermectin
WO2003030653A2 (en) * 2001-10-05 2003-04-17 Rubicon Scientific Llc Animal feeds including actives and methods of using same
US7052712B2 (en) * 2001-10-05 2006-05-30 Rubicon Scientific Llc Animal feeds including actives and methods of preparing same
US7087575B2 (en) * 2002-07-18 2006-08-08 Mayo Foundation For Medical Education And Research Treating the effect of nicotine
US7252836B2 (en) * 2003-01-13 2007-08-07 Penwest, Ltd. Food and feed compositions including resistant starch
NO319624B1 (no) 2003-09-15 2005-09-05 Trouw Internat Bv Fiskefôr for laksefisk i ferskvann og anvendelse av slikt fôr.
WO2005048998A1 (en) * 2003-11-21 2005-06-02 Commonwealth Scientific & Industrial Research Organisation G i tract delivery systems
ITMI20040187A1 (it) * 2004-02-06 2004-05-06 Cosmo Spa Composizioni farmaceutiche o dietetiche a base di acidi grassi a catena corta e zuccheri complessi per le disfunzioni intestinali
WO2005105851A1 (en) * 2004-04-28 2005-11-10 Commonwealth Scientific & Industrial Research Organisation Starch treatment process
US20080126195A1 (en) 2004-07-22 2008-05-29 Ritter Andrew J Methods and Compositions for Treating Lactose Intolerance
PL216229B1 (pl) * 2007-01-25 2014-03-31 Biolek Społka Z Ograniczoną Odpowiedzialnością Preparat zawierający maślan sodu i zastosowanie preparatu zawierającego maślan sodu
US20080233260A1 (en) * 2007-03-22 2008-09-25 Mgp Ingredients, Inc. Resistant starch-hydrocolloid blends and uses thereof
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP3239170B1 (de) 2008-06-04 2019-03-20 Synergy Pharmaceuticals Inc. Für die behandlung von gastrointestinalen erkrankungen, entzündungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
EP3241839B1 (de) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Zur behandlung von erkrankungen des magen-darm-trakts, entzündlichen erkrankungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
KR20110124780A (ko) 2009-02-24 2011-11-17 리터 파마슈티컬즈 인코오포레이티드 프리바이오틱 제제 및 사용 방법
WO2011137249A1 (en) 2010-04-28 2011-11-03 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
GB201213629D0 (en) * 2012-07-31 2012-09-12 Imp Innovations Ltd Compounds and their effects on appetite control and insulin sensitivity
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US20160183563A1 (en) * 2013-07-30 2016-06-30 Benemilk Oy Feed for lactating ruminants
CN105592711A (zh) * 2013-07-30 2016-05-18 拜内梅尔克公司 用于泌乳反刍动物的饲料
EP3054969B1 (de) 2013-10-10 2021-03-10 Bausch Health Ireland Limited Gunaylatcyclase-cyclase-agonisten zur behandlung von opioidinduzierten störungen
WO2015091885A2 (en) 2013-12-20 2015-06-25 Fresenius Kabi Deutschland Gmbh Microcapsules with polymeric coating comprising a lipid and an active agent
US20160158174A1 (en) * 2014-12-09 2016-06-09 Intercontinental Great Brands Llc Enteric-Coated Functional Food Ingredients And Methods For Making The Enteric-Coated Functional Food Ingredients
JP2019506383A (ja) 2016-01-11 2019-03-07 シナジー ファーマシューティカルズ インコーポレイテッド 潰瘍性大腸炎を治療するための製剤および方法
JP7097027B2 (ja) * 2016-08-10 2022-07-07 モナッシュ ユニバーシティ 自己免疫疾患の処置及び予防のための代謝物
JP2018158895A (ja) * 2017-03-22 2018-10-11 株式会社ダイセル 制御性t細胞増加剤、食品、及び医薬
JP7136807B2 (ja) 2017-04-17 2022-09-13 ザ・ユニバーシティ・オブ・シカゴ ヒトの健康及び疾患の治療用途向けの短鎖脂肪酸の腸への送達用ポリマー材料
BE1025137B1 (nl) * 2017-12-22 2018-11-09 Nutri-Ad International Nv Diervoeder materiaal
JP2020066606A (ja) * 2018-10-25 2020-04-30 株式会社ダイセル 1型ヘルパーt細胞増加剤、食品、及び医薬
DK180688B1 (da) * 2020-02-11 2021-11-26 Sander Wilbek Theis Stivelsespropanoat anvendt som fodertilsætningsstof og/eller foderingrediens til landbrugsdyr, havbrugsdyr og fiskeopdræt til at fremme væksten og/eller opnåelse af hurtigere vægtforøgelse
WO2021195087A1 (en) 2020-03-23 2021-09-30 Bay State Milling Company Rapid high amylose wheat seed purity test
WO2023098964A1 (es) * 2021-12-01 2023-06-08 Jimenez Meza Martin Francisco Compuesto de propionato pectinato de cromo, para administrarlo vía oral y sea absorbido en el intestino grueso, para el mejoramiento en el rendimiento deportivo y contra el síndrome metabólico

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5039703A (en) * 1989-11-16 1991-08-13 Breuer Richard I Method for treating inflammatory bowel disorders
CA2082156A1 (en) * 1990-05-04 1991-11-05 Amnon Sintov Colonic drug delivery system
SE9002339L (sv) * 1990-07-04 1992-01-05 Kabi Pharmacia Ab Terapeutisk komposition och foerfarande foer dess framstaellning
AU651626B2 (en) * 1990-10-24 1994-07-28 Nestec S.A. Medical foods having soluble fiber
US5444054A (en) * 1994-04-01 1995-08-22 Abbott Labatories Method of treating ulcerative colitis

Also Published As

Publication number Publication date
EP0730447A4 (de) 1999-01-27
DE69429927T2 (de) 2002-11-07
JPH09505060A (ja) 1997-05-20
WO1995013801A1 (en) 1995-05-26
EP0730447A1 (de) 1996-09-11
CA2176719C (en) 2007-09-18
CA2176719A1 (en) 1995-05-26
EP0730447B1 (de) 2002-02-20
JP4071823B2 (ja) 2008-04-02
US5840860A (en) 1998-11-24

Similar Documents

Publication Publication Date Title
DE69429927D1 (de) Fettsäure-abgabesystem
FI950910A0 (fi) Rasvahappojohdannaiset
DE69433571D1 (de) Verkaufsstellensystem
NO942613D0 (no) Robot-skjæresystem
DE69423837T2 (de) Taktversorgungssystem
DE69432477D1 (de) Brennstoffzufuhrsystem
IT1271302B (it) Sistema di continuita' per alimentazione elettrica
DE59402189D1 (de) 2-Keto-3-methyl-4-hydroxy-valeriansäure
DE69606053T2 (de) Modifizierte fluorsulfonsäure
DE59305938D1 (de) Pyridyloxy-acrylsäureester
DK0464381T3 (da) 2-Methoximinocarboxylsyreestere
NO955230D0 (no) Strömforsyningssystem
DE69433489D1 (de) Keratorefraktives system
KR960700242A (ko) 8-메톡시퀴놀론카르복실산 유도체(8-methoxyquinolonecarboxylic acid derivative)
NO930722L (no) Imidazolylsubstituerte fenyleddiksyreamider
AT399801B (de) Fütterungsanlage
DE59402621D1 (de) Fluor-trifluormethylbenzoesäure-Derivate
DE59205221D1 (de) 1-Alkoxyhexatrien-2-carbonsäureester
NO306159B1 (no) 5-arylisoksazol-4-substituerte 2-aminokarboksylsyreforbindelser
FI961520A (fi) Heribisidiset atsabisfosfonihappoyhdisteet
DE9313287U1 (de) Beschriftungsanlage
DE9307013U1 (de) Sarg-in-Sarg-System
DE59401244D1 (de) Stromversorgungsanlage
DE4494360T1 (de) Stromversorgungssystem
DE69311355D1 (de) Persäure-verbindungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition